BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34866311)

  • 1. Recommended scoring approach for the pediatric patient-reported outcomes version of the Common Terminology Criteria for Adverse Events.
    Hinds PS; Pinheiro LC; McFatrich M; Waldron M; Baker JN; Mowbray C; Maurer SH; Cheng Y; Reeve BB; Wang J
    Pediatr Blood Cancer; 2022 Jun; 69(6):e29452. PubMed ID: 34866311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the caregiver Pediatric Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events measure.
    Reeve BB; McFatrich M; Lin L; Lucas NR; Mack JW; Jacobs SS; Withycombe JS; Baker JN; Freyer DR; Hinds PS
    Cancer; 2021 May; 127(9):1483-1494. PubMed ID: 33332590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events.
    Reeve BB; McFatrich M; Mack JW; Maurer SH; Jacobs SS; Freyer DR; Withycombe JS; Baker JN; Castellino SM; Lin L; Lucas NR; Hinds PS
    J Natl Cancer Inst; 2020 Nov; 112(11):1143-1152. PubMed ID: 31999349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
    McFatrich M; Brondon J; Lucas NR; Hinds PS; Maurer SH; Mack JW; Freyer DR; Jacobs SS; Baker JN; Mowbray C; Wang M; Castellino SM; Barz Leahy A; Reeve BB
    Cancer; 2020 Jan; 126(1):140-147. PubMed ID: 31553494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative.
    Reeve BB; McFatrich M; Pinheiro LC; Weaver MS; Sung L; Withycombe JS; Baker JN; Mack JW; Waldron MK; Gibson D; Tomlinson D; Freyer DR; Mowbray C; Jacobs S; Palma D; Martens CE; Gold SH; Jackson KD; Hinds PS
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27650708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer.
    Reeve BB; McFatrich M; Pinheiro LC; Freyer DR; Basch EM; Baker JN; Withycombe JS; Sung L; Mack JW; Waldron MK; Mowbray C; Palma D; Hinds PS
    J Pain Symptom Manage; 2017 Apr; 53(4):759-766. PubMed ID: 28062347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of Concordance in Symptomatic Adverse Event Reporting by Children, Clinicians, and Caregivers: Implications for Cancer Clinical Trials.
    Freyer DR; Lin L; Mack JW; Maurer SH; McFatrich M; Baker JN; Jacobs SS; Lucas N; Withycombe JS; Tomlinson D; Villabroza KR; Waldron MK; Hinds PS; Reeve BB
    J Clin Oncol; 2022 May; 40(15):1623-1634. PubMed ID: 35294262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subjective Toxicity Profiles of Children in Treatment for Cancer: A New Guide to Supportive Care?
    Hinds PS; Weaver MS; Withycombe JS; Baker JN; Jacobs SS; Mack JW; Maurer SH; McFatrich M; Pinheiro LC; Reeve BB; Wang J
    J Pain Symptom Manage; 2021 Jun; 61(6):1188-1195.e2. PubMed ID: 33096220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
    Dueck AC; Scher HI; Bennett AV; Mazza GL; Thanarajasingam G; Schwab G; Weitzman AL; Rogak LJ; Basch E
    JAMA Oncol; 2020 Feb; 6(2):e193332. PubMed ID: 31556911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events.
    Speck RM; Lenderking WR; Shaw JW
    J Patient Rep Outcomes; 2017; 2():35. PubMed ID: 30175317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Hay JL; Atkinson TM; Reeve BB; Mitchell SA; Mendoza TR; Willis G; Minasian LM; Clauser SB; Denicoff A; O'Mara A; Chen A; Bennett AV; Paul DB; Gagne J; Rogak L; Sit L; Viswanath V; Schrag D; Basch E;
    Qual Life Res; 2014 Feb; 23(1):257-69. PubMed ID: 23868457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
    Lee MK; Schalet BD; Cella D; Yost KJ; Dueck AC; Novotny PJ; Sloan JA
    J Patient Rep Outcomes; 2020 Dec; 4(1):106. PubMed ID: 33305344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Chung AE; Shoenbill K; Mitchell SA; Dueck AC; Schrag D; Bruner DW; Minasian LM; St Germain D; O'Mara AM; Baumgartner P; Rogak LJ; Abernethy AP; Griffin AC; Basch EM
    J Am Med Inform Assoc; 2019 Apr; 26(4):276-285. PubMed ID: 30840079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Swahili translation and cultural adaptation of the pediatric patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
    Schroeder KM; Rizzieri T; Lion RR; Mtenga N; Gisiri M; McFatrich M; Reeve BB
    J Patient Rep Outcomes; 2023 Jun; 7(1):56. PubMed ID: 37306774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electronic symptom monitoring in pediatric patients hospitalized for chemotherapy.
    Leahy AB; Schwartz LA; Li Y; Reeve BB; Bekelman JE; Aplenc R; Basch EM
    Cancer; 2021 Aug; 127(16):2980-2989. PubMed ID: 33945640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptom Adverse Events and Quality of Life of Children With Advanced Cancer: Results From a Longitudinal Study Using the Pediatric Patient-Reported Outcomes-Common Terminology Criteria for Adverse Events.
    Grinde K; Raybin JL; Ward J; Smith C; Brown R; Montgomery KE
    J Pediatr Hematol Oncol Nurs; 2024; 41(1):5-15. PubMed ID: 37697734
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE.
    Watson GA; Veitch ZW; Shepshelovich D; Liu ZA; Spreafico A; Abdul Razak AR; Bedard PL; Siu LL; Minasian L; Hansen AR
    Br J Cancer; 2022 Nov; 127(9):1629-1635. PubMed ID: 36008705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Basch E; Becker C; Rogak LJ; Schrag D; Reeve BB; Spears P; Smith ML; Gounder MM; Mahoney MR; Schwartz GK; Bennett AV; Mendoza TR; Cleeland CS; Sloan JA; Bruner DW; Schwab G; Atkinson TM; Thanarajasingam G; Bertagnolli MM; Dueck AC
    Clin Trials; 2021 Feb; 18(1):104-114. PubMed ID: 33258687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal use of patient reported outcomes in pediatric leukemia and lymphoma reveals clinically relevant symptomatic adverse events.
    Jacobs SS; Withycombe JS; Castellino SM; Lin L; Mack JW; McFatrich M; Baker JN; Freyer DR; Maurer SH; Mowbray C; Hinds PS; Reeve BB
    Pediatr Blood Cancer; 2022 Dec; 69(12):e29986. PubMed ID: 36151978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying symptomatic adverse events using the patient-reported outcomes version of the common terminology criteria for adverse events in patients with non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.
    Zhu Y; Jean-Baptiste M; Lenderking WR; Bell JA; Revicki DA; Lin HM; Brake R; Reeve BB
    Cancer Med; 2023 Mar; 12(5):5494-5505. PubMed ID: 36583557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.